Cost-effectiveness of adult pertussis vaccination in Germany (Q40083219)

17 September 2017

Cost-effectiveness of adult pertussis vaccination in Germany (English)

1 reference

Carl Heinz Wirsing von König

17 September 2017

0 references

series ordinal

3

object named as

Carl Heinz Wirsing von Konig

1 reference

17 September 2017

1

Grace M Lee

1 reference

17 September 2017

Marion Riffelmann

2

1 reference

PubMed ID

18538901

17 September 2017

language of work or name

English

0 references

publication date

19 May 2008

1 reference

17 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

17 September 2017

26

1 reference

17 September 2017

29-30

1 reference

17 September 2017

3673-3679

1 reference

The control of pertussis--2007 and beyond

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Pertussis of adults and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Symptoms and complications of pertussis in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Societal costs and morbidity of pertussis in adolescents and adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Morbidity of pertussis in adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

The changing age and seasonal profile of pertussis in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Cost effectiveness of pertussis vaccination in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

[Pertussis: incidence, symptoms and costs]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Health-state valuations for pertussis: methods for valuing short-term health states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Efficacy of an acellular pertussis vaccine among adolescents and adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

EPIDEMIOLOGY OF A SMALL PERTUSSIS OUTBREAK IN KENT COUNTY, MICHIGAN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Duration of immunity against pertussis after natural infection or vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Bordetella pertussis and Chronic Cough in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Adolescent and adult pertussis vaccination: computer simulations of five new strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Household contact study of Bordetella pertussis infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Severe and unrecognised: pertussis in UK infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Infant pertussis: who was the source?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Pertussis in German adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Pertussis in adults: frequency of transmission after household exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Transmission of Bordetella pertussis to young infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Pertussis in adolescents and adults: should we vaccinate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Risk of Anaphylaxis After Vaccination of Children and Adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

[Public health costs of influenza in Germany 1996- a cost-of-illness analysis]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.068

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.04.068

1 reference

17 September 2017

1 reference

PubMed ID

18538901